Oral Cancer Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026

The oral cancer therapeutics market share is expected to increase by USD 1.14 billion from 2021 to 2026, and the market's growth momentum will decelerate at a CAGR of 7.5%.

This oral cancer therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers oral cancer therapeutics market segmentation by product (targeted therapy and chemotherapy) and geography (North America, Europe, Asia, and Rest of World (ROW)). The oral cancer therapeutics market report also offers information on several market vendors, including Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cipla Ltd., Eli Lilly and Co., Endo International Plc, F. Hoffmann La Roche Ltd., Fresenius Kabi AG, GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Lupin Ltd., Merck and Co. Inc., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc. among others.

What will the Oral Cancer Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Oral Cancer Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Oral Cancer Therapeutics Market: Key Drivers, Trends, and Challenges

The increasing incidence and prevalence of oral cancer is notably driving the oral cancer therapeutics market growth, although factors such as side effects of chemotherapeutics may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the oral cancer therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Oral Cancer Therapeutics Market Driver

One of the key factors driving growth in the oral cancer therapeutics market is the increasing incidence and prevalence of oral cancer. The global oral cancer therapeutics market has witnessed the development of new therapeutics and increasing advances in diagnostic modalities for oral cancer. The number of new cases of oral cancer has increased in recent years. Oral cancers are more common in men than in women. Despite the availability of chemotherapy and targeted therapy, the mortality rate has increased due to the lack of diagnosis of cancer in its early stages. The increase in prevalence, incidence, and mortality rate of oral cancer has resulted in a huge unmet need for therapeutics in the market, which is expected to attract pharmaceutical vendors to enter the market with novel therapies, thereby driving the market growth.

Key Oral Cancer Therapeutics Market Trend

The increase in R and D of new drugs is an oral cancer therapeutics market trend that is expected to have a positive impact in the coming years. The market has several chemotherapy drugs and only a few targeted therapies approved for the treatment of oral cancer. Due to the increasing prevalence of oral cancer and the need for novel therapeutics for treatment, several vendors are focused on the development of novel therapeutics and combination therapies to treat oral cancer. For instance, Gliknik Inc. (Gliknik) is developing biropepimut-S (GL-0817) to treat squamous cell carcinoma of the oral cavity. It is a peptide immunomodulator targeted against important epitopes within the cancer protein MAGE-A3 and prevents the recurrence of high-risk squamous cell carcinoma of the oral cavity. Biropepimut-S (GL-0817) is currently in a double-blind, placebo-controlled clinical trial in seven countries. There are several other drugs under development, which are listed below. Celldex Therapeutics Inc. (Celldex Therapeutics), a subsidiary of Avant Immunotherapeutics Inc. (Avant Immunotherapeutics), is evaluating safety and tolerability of the combination therapy of CDX-3379 and cetuximab in Phase-II clinical trials to treat advanced head and neck squamous cell carcinomas, which include oral cavity cancers.

Key Oral Cancer Therapeutics Market Challenge

The side effects of chemotherapeutics will be a major challenge for the oral cancer therapeutics market during the forecast period. The side effects of chemotherapeutics are a major concern for patients despite the improved efficacy and greater survival rates of new treatments. Side effects such as vomiting and nausea are the most commonly experienced by patients undergoing chemotherapy for cancer. Delayed acute chemotherapy-induced nausea and vomiting are difficult to manage in patients. Similarly, the gastrointestinal side effects of chemotherapy are the second-most common and can be painful and potentially fatal for patients. They may cause local ulceration and pain in patients, leading to malabsorption, anemia, and fatigue. Chemotherapeutics such as Carboplatin, 5-fluorouracil, paclitaxel (TAXOL), docetaxel (TAXOTERE), and hydroxyurea are used in the treatment of oral cancer. These chemotherapeutics have several side effects that may hinder patient compliance.

This oral cancer therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global oral cancer therapeutics market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the oral cancer therapeutics market during the forecast period.

Who are the Major Oral Cancer Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Amneal Pharmaceuticals Inc.
• AstraZeneca Plc
• Bristol Myers Squibb Co.
• Cipla Ltd.
• Eli Lilly and Co.
• Endo International Plc
• F. Hoffmann La Roche Ltd.
• Fresenius Kabi AG
• GlaxoSmithKline Plc
• Intas Pharmaceuticals Ltd.
• Lupin Ltd.
• Merck and Co. Inc.
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Viatris Inc.

 

This statistical study of the oral cancer therapeutics market encompasses successful business strategies deployed by the key vendors. The oral cancer therapeutics market is fragmented and the vendors are deploying growth strategies such as focusing on expanding their production capacity, adopting innovative technologies, testing and launching products, promoting awareness and patient assistance programs and engaging in mergers and acquisitions to meet the demand for the treatment of oral cancer to compete in the market.

Product Insights and News

• amneal.com - The company is involved in offering a wide range of organometallics such as aluminum alkyls, magnesium alkyls among others used for varieties of applications such as making polyethylene packaging and toys, pharmaceuticals and electronic devices, etc.

• amneal.com - The company develops lithium-based materials for a wide range of industries and end markets.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The oral cancer therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Oral Cancer Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the oral cancer therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Oral Cancer Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

51% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for oral cancer therapeutics in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The strong prevalence of oral cancer in the US will facilitate the oral cancer therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 negatively impacted the healthcare industry in the region. Due to the effect of COVID-19, a large number of oral cancer treatment companies were forced to lay off employees. In 2021, with the increased number of vaccination and the resumption of operations in the healthcare units, there were higher inflows of patients resuming their oral cancer treatment in healthcare facilities in this region. 

What are the Revenue-generating Product Segments in the Oral Cancer Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The oral cancer therapeutics market share growth by the targeted therapy segment will be significant during the forecast period. Oral cancer is associated with a high mortality rate. According to the Oral cancer foundation, approximately 10,000 across the globe die from oral cancer each year. Although the treatment landscape has been having the presence of chemotherapy drugs, the strongly associated side effects and the recurring nature of malign tumors create a huge unmet need in the market. To address this unmet need, the market has been witnessing the development of novel drugs in the form of targeted therapies over the last few years.

This report provides an accurate prediction of the contribution of all the segments to the growth of the oral cancer therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Oral Cancer Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Decelerate at a CAGR of 7.5%
Market growth 2022-2026	$ 1.14 billion
Market structure	Fragmented
YoY growth (%)	8.71
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 51%
Key consumer countries	US, Canada, Germany, UK, and India
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cipla Ltd., Eli Lilly and Co., Endo International Plc, F. Hoffmann La Roche Ltd., Fresenius Kabi AG, GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Lupin Ltd., Merck and Co. Inc., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Oral Cancer Therapeutics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive oral cancer therapeutics market growth during the next five years
• Precise estimation of the oral cancer therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the oral cancer therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of oral cancer therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch